Provider review, September 2026
Strut labels its own product a compounded off-label prescription inside its own comparison table — and carries a 2026 federal warning letter that names its website by address. This site discloses the letter and does not score it.
Strut Health is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Most sellers put the compounding disclaimer at the foot of the page in grey text. This one puts it in the feature table it uses to sell against synthetic growth hormone, as a row with a yes or a no in each column.
The two forms it sells are marked yes; the alternative it is competing against is marked no. A reader comparing options sees the regulatory category as a feature, next to the dosing frequency and the price, rather than as a legal afterthought.
That is unusually candid framing and it is the main reason to read this seller at all.
The injectable is described on its card as a monthly vial. The oral lozenge on the same card row is described as a thirty-day supply. Those are not the same unit, and the seller's own comparison table then calls both of them monthly.
This site records the card wording, because the card is where the product is sold and because a thirty-day supply and a billing month are different things. The disagreement between the two halves of one page is recorded rather than reconciled.
The dosing frequency is published beside each: one lozenge daily for the oral form, five days on and two days off for the injection. That is more dosing detail than most rows here carry.
The homepage publishes no price at all, so a reader who never reaches the product page sees nothing.
Screening the operating company by name against the regulator's live index returns a letter issued against it in February 2026. The letter was fetched and read: it is addressed to the company at its own street address and its own support email, and its first paragraph names this seller's website by address.
The subject is false or misleading claims about compounded weight-loss drugs, reviewed on that website. It concerns the weight-loss line rather than the peptide line.
On this site a warning letter is disclosed and never scored. It moves no position on any board and changes no figure. It is recorded because a reader deciding where to spend money is entitled to know it exists.
The terms also name a second company, the medical group that employs the prescribers, and say plainly that those prescribers are not employed by the platform.
Strut Health received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.
Auren Rx names both its prescribing group, Wasef Health, and its dispensing pharmacy, VialsRX in Houston, with street addresses and phone numbers, and lets a subscriber pause an auto-refill plan on NAD+, sermorelin, glutathione or GHK-Cu instead of forcing a full cancellation.
Auren Rx is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Auren RxYes. One was issued against the operating company in February 2026 over false or misleading claims about compounded weight-loss drugs, and it names this seller's website by address. It is disclosed here and does not affect any score or position.
No. It concerns the compounded weight-loss products the regulator reviewed on the same website.
Not on the product card: the injection is a monthly vial and the lozenge a thirty-day supply. The comparison table lower down calls both monthly.
A separately named medical group. The terms say plainly that providers are not contracted or employed by the platform company.
No. The seller says it works with compounding pharmacists and does not name a facility.
Strut Health is not a paid partner; this link may earn a commission if that changes. Full disclosure.